NCT02044120View on ClinicalTrials.gov

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Ewing Sarcoma
Interventions
DRUG

niraparib

DRUG

Temozolomide

DRUG

Irinotecan

Trial Locations (5)

20892

National Cancer Institute, Bethesda

48106

University of Michigan, Ann Arbor

90027

Children's Hospital of Los Angeles, Los Angeles

98101

Seattle's Children Cancer Center, Seattle

W1T 7HA

University College London Hospital, London

All Listed Sponsors
lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT02044120 - ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | Biotech Hunter | Biotech Hunter